One of the biggest barriers to the adoption of any new biotechnology tool is validation and regulatory clarity.

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

Life science researchers have developed tools that scan millions of papers weekly for signs of fraud, but detection remains challenging.

A novel optogenetic screening platform enables a high-throughput screen and identified several integrated stress response-potentiating compounds.

For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of which can kill neurons and impact the brain’s abil ...

The compatibility of technologies is critical to the commercialization of advanced therapies in the biotechnology industry.

Biopharma got perilously close to having demand for uniquely skilled and experienced workers outstrip supply during the COVID ...

The portrayal of uncaring scientists without any thought for the animals being used in their research is far from the truth.

The Wacker Biotechnology Center is in Munich, where the company has been conducting fundamental research for over a century.

This could lead to the development of precision allergy treatments that are fast acting, needle free, and tailored to individual allergen sensitivities.

The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.